...A. There are present at this meeting in person or through representation by proxy 123,491,338 shares of common stock, representing approximately 95% of the outstanding shares of common stock of the company as of 8:30 AM Eastern Time this morning. B. In addition, a majority of the company's outstanding shares have been voted in favor of the resolution to approve an amendment to our restated certificate of incorporation allowing for officer exculpation. C. This holds true across many dimensions with tangible results that include outstanding R&D productivity that has validated an entirely new class of medicines, produced an outsized probability of clinical success relative to the rest of the industry, and delivered a commercial portfolio of six medicines, a rich pipeline with numerous multi-billion dollar opportunities where we expect over 25 high value programs across diverse indications by the end D. Leading commercial capabilities, generating over $1.6 billion in annual product sales in...
